Evogene Ltd. (NASDAQ: EVGN)

Evogene Ltd. specializes in the development of a pioneering computational chemistry platform designed to generate small molecules for the pharmaceutical and agricultural industries. The company leverages its proprietary ChemPass AI engine to discover and optimize small molecules, addressing the challenges of limited chemical space exploration and the need for simultaneous optimization of multiple parameters. Evogene's technology aims to increase the probability of success and reduce the time and cost associated with small molecule discovery.

Evogene generates revenue through collaborations with industry partners, pooling resources to drive joint product development. The company's revenue streams typically include upfront payments, research and development fees, and royalties from sales of end-products. Evogene's primary products and services revolve around its ChemPass AI engine, which is utilized for the discovery and optimization of small molecules for drugs and ag-chemicals such as herbicides, insecticides, and fungicides. The company's customer base includes leading global agricultural-chemical companies and pharmaceutical collaborators.

• AgPlenus: AgPlenus focuses on the discovery and development of novel ag-chemical products, leveraging Evogene's ChemPass AI tech engine. The segment aims to design effective and sustainable crop protection products by implementing a target-based approach for identifying and developing new modes of action for crop protection products. AgPlenus collaborates with major ag-chemical companies such as Bayer and Corteva, catering to the agricultural industry. The segment's product development pipeline includes programs for herbicides and fungicides, targeting specific pests and diseases. AgPlenus's business model involves licensing product candidates and engaging in research and development collaborations, generating revenue through upfront payments, milestone payments, and royalties.

• Biomica: Biomica is focused on the discovery and development of innovative human microbiome-based therapeutics. The segment aims to leverage the human microbiome's beneficial functions to support life and address various medical disorders. Biomica's product pipeline includes BMC128, a microbiome-based therapeutic designed to enhance anti-tumor immune activity. The segment collaborates with pharmaceutical companies and has entered into an exclusive worldwide licensing agreement with Shanghai Lishan Biopharmaceuticals Co. for BMC128.

• Casterra Ag: Casterra Ag focuses on the development of an integrated solution for castor cultivation, including advanced non-GMO high-yielding castor seed varieties, compatible agricultural machinery, and agronomic protocols. The segment targets the castor oil market, which is used for the production of bio-based products for various industrial applications. Casterra Ag collaborates with companies such as ENI Kenya B.V. for the cultivation of castor seeds at a commercial scale for biofuel production.

Evogene operates in a competitive landscape within the ag-chemical and pharmaceutical industries. Key competitors include major seed and ag-chemical companies such as BASF, Bayer, Syngenta Group, FMC, and Corteva, as well as mid-size ag-chemical companies and small to mid-size biotech companies. Evogene's competitive advantages lie in its proprietary ChemPass AI engine, which enables the discovery and optimization of small molecules with increased efficiency and reduced costs. The company's collaborations with leading industry partners further strengthen its position in the market.

Evogene's customer base includes leading global agricultural-chemical companies and pharmaceutical collaborators. The company's collaborations with major players in the industry, such as Bayer and Corteva, highlight its strategic partnerships and the demand for its innovative solutions. Evogene's focus on leveraging its proprietary technology to address industry challenges positions it as a key player in the computational chemistry and small molecule discovery space.